Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: A case report and literature review

Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: A case report and literature review

Oro-maxillo-facial metastasis from hepatocellular carcinoma (HCC) is very rare, and reports on treating maxillary metastasis from HCC are unavailable. Anti-angiogenesis therapy combined with immunotherapy represented by programmed cell death 1 (PD-1) or its ligand (PD-L1) inhibitor has become the st...

Full description

Bibliographic Details
Main Authors: Xuexia Liang, Qiaodan Liu, Wei Yao, Shuqin Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
hepatocellular carcinoma
maxillary metastasis
PD-1 inhibitor
bevacizumab
chemoradiotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.941454/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.941454/full

Similar Items